id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-N-0402-0032,FDA,FDA-2013-N-0402,Testimony from Association for Accessible Medicine,Other,Testimony,2017-05-17T04:00:00Z,2017,5,2017-05-17T04:00:00Z,,2017-05-17T14:02:11Z,,0,0,09000064825cd8d3
FDA-2013-N-0402-0029,FDA,FDA-2013-N-0402,Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public Workshop; Request for Comments,Notice,Request for Comments,2017-03-14T04:00:00Z,2017,3,2017-03-14T04:00:00Z,2017-06-03T03:59:59Z,2017-06-03T13:00:35Z,2017-04981,0,0,0900006482505faf